03.20.2026
Neusignal Therapeutics , a clinical stage neuroscience biotechnology company , announced positive safety and tolerability from Phase 1 clinical trial of Alzheimer’s disease candidate, NTX 083.
In the Phase 1 repeat dose clinical study in healthy adult volunteers, including Japanese and Caucasian participants, NTX 083 was well tolerated and demonstrated a favorable safety profile across all standard clinical assessments.
Based on this successful milestone, Neusignal Therapeutics plans to initiate a Phase 1b clinical trial in the United States, which will evaluate NTX-083 in patients with Alzheimer’s disease.
To view the original announcement, click here: https://neusignal-tx.com/en/news/20260317-3/
About Neusignal Therapeutics
Neusignal Therapeutics is a pioneering biotechnology company based in Tokyo, Japan, focused on the development of innovative therapies for Alzheimer’s disease. Founded as a spin-off from Tohoku University, Neusignal is dedicated to advancing novel drug candidates aimed at slowing the progression of Alzheimer’s, a condition that is rapidly increasing worldwide. With a commitment to addressing the complex challenges of treatment management, high healthcare costs, and patient eligibility, Neusignal strives to bring transformative solutions to those affected by Alzheimer’s. The company is preparing for clinical trials, with plans for both domestic and international development.
About Fast Track Initiative:
Established in 2004, Fast Track Initiative, Inc. (FTI) is a life science venture capital firm focusing its investments on early-stage startups with a strong focus on biotech and therapeutics. FTI has a strict mission to make a ground-breaking impact on the quality of our life and human wellness through investments across a broad range of areas in the life science community including therapeutics, diagnostics, digital health, healthcare services, and more. The company provides valuable, hands-on support to its 30+ portfolio companies through business and R&D strategy, partnering, investor syndication, and more, including access to its network of professionals in Japan.
Visit https://us.fasttrackinitiative.com for more details, or follow us on LinkedIn: https://www.linkedin.com/company/fast-track-initiative/
